As a result, there was no significant difference in PFS between the WT and BRAF-mutated NSCLC patients treated with ICIs monotherapy or combined therapy (HR: 1.00; 95% CI, 0.72 to 1.40; p = 0.91, Fig. 6B). Here, BRAF is linked to non-small cell lung carcinoma.